What is Alpha-1 Antitrypsin Deficiency?
AATD is an inherited, genetic, autosomal co-dominant disorder caused by mutations in the SERPINA1 gene, with the most frequent deficient variants coming from the Z (Glu342Lys) and S alleles (Glu264Val). The presence of Z alleles results in misfolding and polymerization of the AAT, leading to over 95% of severe AATD patients being PIZZ.
About YOLT-202
YOLT-202 is an in vivo gene-editing therapy that corrects PiZ mutation to PiM for the treatment of AATD. Utilizing YolTech’s proprietary adenine base editor, YOLT-202 is engineered to achieve on-target editing with minimal bystander activity.
Latest News
-
Apr 28, 2025
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial HypercholesterolemiaRead More
-
Mar 26, 2025
YolTech Therapeutics Announces Favorable Interim Results from Ongoing IIT that Single-Dose Administration of YOLT-101, an In Vivo Gene Editing Therapy, Effectively Reduces LDL-C in Familial HypercholesterolemiaRead More
-
Mar 21, 2025
YolTech Therapeutics Announces GMP Manufacturing Facility Expansion to Support Gene Editing Therapy Commercial ManufacturingRead More
